Goldman Sachs
RCPI

Goldman Sachs’s ROCK CREEK PHARMACEUTICALS INC COM STK (DE) RCPI Stock Holding History

Goldman Sachs’s Portfolio RCPI Stock Details RCPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,826
Closed -$16K – 7788
2015
Q2 		$16K Sell
10,826
-3,192
-23% -$7.6K ﹤0.01% 7111
2015
Q1 		$36K Sell
14,018
-98
-0.7% -$386 ﹤0.01% 6791
2014
Q4 		$64K Sell
14,116
-3,972
-22% -$20.9K ﹤0.01% 6737
2014
Q3 		$127K Buy
18,088
+5,751
+47% +$56.8K ﹤0.01% 6463
2014
Q2 		$182K Buy
+12,337
New +$214K ﹤0.01% 6265

Other funds holding RCPI

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs's RCPI Position: Q3 2015 in Review

Goldman Sachs sold out of ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) in Q3 2015, closing a stake of 10,826 shares — an estimated $16K sold.

Goldman Sachs first reported a position in RCPI in Q2 2014 and held it in 5 quarters. The position peaked at $182K in Q2 2014. 37 funds tracked by Wall St. Rank hold RCPI as of Q3 2015.

  • Goldman Sachs reported no remaining ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position as of Q3 2015 after selling out during the quarter.
  • Goldman Sachs sold 10,826 ROCK CREEK PHARMACEUTICALS INC COM STK (DE) shares in Q3 2015, an estimated $16K.
  • Goldman Sachs first reported a position in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) in Q2 2014 and held it in 5 quarters.
  • Goldman Sachs's ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position peaked at $182K in Q2 2014.
  • 37 funds tracked by Wall St. Rank held ROCK CREEK PHARMACEUTICALS INC COM STK (DE) as of Q3 2015.

Based on Goldman Sachs's 13F filing for Q3 2015, filed 13 Nov 2015.